Relmada Therapeutics 주식 (NASDAQ: RLMD)

에 대한 최신 뉴스 Relmada Therapeutics (NASDAQ:RLMD) 주식

Relmada Therapeutics

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Premarket Trading

Opinion

Trading Ideas

EPSN

RLMD

매일 많은 이야기와 논의가 내부자 매수에 대해 인터넷에 올라온다. 대부분은 기업 내부자들의 매수 및 매도 활동에 대한 연구가 책 표지의 소개글을 읽는 데 그치는 사람들에 의해 작성된 것처럼 보인다. 일부 내부자 매수는 중요하다. 반면, 일부는 도움이 거의 안된다.

시장을 일관되게 능가하는 내부자 거래를 찾는 방법 - 언더 더 레이더

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics Inc

Piper Sandler set a $400 price target for Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) following Tuesday's Q1 earnings call.
What Happened: The investment bank confirmed the price target on Wednesday, with analyst Alex Potter reiterating an overweight rating on the stock despite Tesla's poor performance in the latest quarter.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">NEWS: Piper Sandler analyst Alex Potter he reiterated an Overweight rating and $400 price target on <a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a>. &quot;In our preview last week, we predicted that (at best) Q1 would be a non-event. With the stock trading up slightly in the after-hours session, it appears our best-case…
&mdash; Sawyer Merritt (@SawyerMerritt) <a href="https://twitter.com/SawyerMerritt/status/1915058306160148706?ref_src=twsrc%5Etfw">April 23, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
"In our preview last week, we predicted that (at best) Q1 would be a non-event. With the stock trading up slightly in the after-hours session, it appears our best-case scenario has materialized," the investment bank said.
Piper Sandler also maintained that Tesla didn't ‘hedge expectations' by announcing plans for launching the robotaxis, as well as more affordable models. Referring to the robotaxi launch in June, the statement then mentioned how there were some "interesting catalysts" for the investors ahead.&nbsp;
However, the investment bank did mention that it would largely depend on how Tesla's product launches, like the robotaxi and affordable models, materialize. "We reiterate our $400 price target,&#8221; Piper Sandler said.
Why It Matters: Piper Sandler isn't the only one optimistic about Tesla, with <a href="https://www.benzinga.com/25/04/44945402/wedbushs-dan-ives-raises-teslas-price-target-to-350-as-musk-promises-to-significantly-reduce-doge-time">Wedbush Investment's Dan Ives </a>also setting a price target of $350 on Tesla stock.
The analysts' optimism stems from Elon Musk reiterating his commitment to the EV giant as the <a href="https://www.benzinga.com/25/04/44940401/elon-musk-says-hell-only-spend-day-or-two-per-week-on-government-matters-to-ensure-fraud-does-not-come-roaring-back-ceos-focus-to-shift-to-tesla-beginning-may">billionaire will scale back </a>on his DOGE duties with the Trump administration.
The company also announced it will <a href="https://www.benzinga.com/25/04/44942792/tesla-q1-earnings-call-company-says-more-affordable-models-launching-this-year">release an affordable model</a>, which will be based on Tesla's current line-up of vehicles like the Model S, Model Y, Model X, Model 3, and the Cybertruck.
However, <a href="https://www.benzinga.com/markets/25/04/44941889/teslas-sweet-little-lies-hide-worst-performance-ever-elon-musks-robot-takeover-talk-is-just-a-smokescreen-says-ross-gerber">analysts like Ross Gerber </a>aren't as optimistic about Tesla. Following the earnings call, the TSLA bull shared his thoughts on the social media platform X, calling it the "worst performance in Tesla's history."
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="190" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24014306/Screenshot-2025-04-24-at-11.09.19-AM-1024x190.jpg" alt="" class="wp-image-885649" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24014306/Screenshot-2025-04-24-at-11.09.19-AM-1024x190.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24014306/Screenshot-2025-04-24-at-11.09.19-AM-300x56.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24014306/Screenshot-2025-04-24-at-11.09.19-AM-768x143.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24014306/Screenshot-2025-04-24-at-11.09.19-AM-1536x285.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24014306/Screenshot-2025-04-24-at-11.09.19-AM.jpg 1744w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
According to Benzinga Edge stock Rankings, Tesla scores well across all metrics except Value. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge</a> today!
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44943387/elon-musk-shares-fsd-update-at-tesla-earnings-call-10-to-20-model-ys-will-offer-paid-robotaxi-rides-in-june">Elon Musk Shares FSD Update At Tesla Earnings Call: &#8217;10 To 20&#8242; Model Ys Will Offer Paid Robotaxi Rides In June</a></li>
</ul>
Image Via Shutterstock

News

Tech

General

TSLA

Piper Sandler Puts $400 Price Target On Tesla: 'It Appears Our Best-Case Scenario Has Materialized'

Helix Energy Solns Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLX#NYSE">HLX</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.03 by 33.33 percent. This is a 166.67 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $278.06 million which missed the analyst consensus estimate of $284.24 million by 2.17 percent. This is a 6.13 percent decrease over sales of $296.21 million the same period last year.

Earnings

Earnings Misses

Helix Energy Solns Gr Q1 EPS $0.02 Misses $0.03 Estimate, Sales $278.06M Miss $284.24M Estimate

Banning Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips won&#8217;t stop China&#8217;s artificial intelligence development, according to Bernstein analysts, who suggest the export restrictions could instead strengthen domestic competitors like Huawei Technologies.
What Happened: &#8220;Banning the H20 would make no sense as its performance is already well below Chinese alternatives; a ban would simply hand the Chinese AI market completely over to Huawei,&#8221; Bernstein analysts wrote Wednesday, <a href="https://www.businessinsider.com/nvidia-chip-export-bans-unlikely-hinder-china-ai-growth-2025-4">reported</a> Business Insider.
The President Donald Trump administration is expected to require licenses for exporting powerful AI semiconductors to China, effectively creating an export ban, <a href="https://www.benzinga.com/25/04/44835247/nvidias-reported-failure-to-inform-chinese-clients-on-new-chip-restrictions-could-give-huawei-a-strategic-edge?utm_source=chatgpt.com">Nvidia disclosed in a regulatory filing last week</a>. 
The company <a href="https://www.benzinga.com/25/04/44830406/nvidia-to-take-55-billion-hit-over-china-chip-export-restrictions-but-top-analyst-dan-ives-says-hes-not-overly-concerned-all-part-of-the-high-game-of-poker">anticipates a $5.5 billion charge</a> related to inventory and purchase commitments for its H20 chip in the first quarter ending April 27.
Chinese companies have been reducing dependence on Nvidia by training models on unrestricted edge devices like personal computers and connecting Huawei chips with Nvidia processors. According to Bernstein&#8217;s channel checks, &#8220;most companies are able to carry on without H20 chips.&#8221;
See Also:&nbsp;<a href="https://www.benzinga.com/news/earnings/25/04/44937440/tesla-q1-misses-estimates-as-tariff-pressures-weigh-on-outlook-lower-cost-evs-still-on-track" target="_blank" rel="noreferrer noopener">Tesla Q1 Misses Estimates As Tariff Pressures Weigh On Outlook, Lower-Cost EVs Still On Track</a>
Why It Matters: Huawei is reportedly preparing <a href="https://www.benzinga.com/25/02/43945751/huawei-boosts-ai-chip-production-despite-taiwan-semi-and-asml-ban-aims-to-challenge-nvidia-in-china?utm_source=chatgpt.com">mass shipments of its advanced 910C AI chip</a> as early as next month. The chip reportedly matches Nvidia&#8217;s H100 performance by integrating two 910B processors into a single package, according to Reuters.
Huawei has doubled the yield rate of its AI chips from about 20% a year ago to approximately 40% now, making its Ascend <a href="https://www.benzinga.com/25/02/43945751/huawei-boosts-ai-chip-production-despite-taiwan-semi-and-asml-ban-aims-to-challenge-nvidia-in-china?utm_source=chatgpt.com">chip production profitable for the first time</a>, the Financial Times reported. The company aims to reach the industry standard of 60% yield.
Chinese AI companies focused on foundation model subscriptions face the biggest challenge transitioning from Nvidia&#8217;s proprietary CUDA software. Bernstein noted one Chinese company required 200 engineers and six months to migrate to Huawei chips, achieving only 90% of previous performance.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/personal-finance/25/04/44889632/warren-buffetts-son-cashed-in-90k-instead-of-waiting-on-500-million-now-hes-using-buffett-bucks-to-build-his-own-dream-town-in-new-york" target="_blank" rel="noreferrer noopener">Warren Buffett&#8217;s Son Cashed In $90K Instead of Waiting on $500 Million — Now He&#8217;s Using ‘Buffett Bucks&#8217; to Build His Own Dream Town in New York</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Asia

Equities

Regulations

Global

Markets

NVDA

Nvidia Chip Ban Won't Stop China's AI Momentum, Say Analysts — Blocking H20 Would Hand Market To Huawei Amid Trump-Era Export Crackdown

Euronet Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEFT#NASDAQ">EEFT</a>) reported quarterly earnings of $1.13 per share which beat the analyst consensus estimate of $1.05 by 7.62 percent. This is a 11.72 percent decrease over earnings of $1.28 per share from the same period last year. The company reported quarterly sales of $915.50 million which beat the analyst consensus estimate of $912.59 million by 0.32 percent. This is a 6.83 percent increase over sales of $857.00 million the same period last year.

Earnings Beats

EEFT

Euronet Worldwide Q1 Adj. EPS $1.13 Beats $1.05 Estimate, Sales $915.50M Beat $912.59M Estimate

In connection with the Secondary Offering, Sportradar agreed to concurrently purchase from the underwriters 3,000,000 Class A ordinary shares at a price per share equal to the price at which the underwriters purchase the shares from the Selling Shareholders in the Secondary Offering (the "Share Repurchase"), subject to the completion of the Secondary Offering. The Share Repurchase is part of the Company's existing $200 million share repurchase program and the Company intends to fund the Share Repurchase with cash on hand. The underwriters will not receive any underwriting fees for the shares being repurchased by the Company. The Secondary Offering is expected to close on April 25, 2025.

SRAD

Sportradar Prices Secondary Share Sale By Insiders At $22.50; Initiates Buyback Of 3M Shares Using Cash Reserves

Nokia lands strategic 5G RAN deal with T-Mobile US to enhance nationwide connectivity
<ul>
<li>Nokia boosts T-Mobile US's award-winning 5G network with network footprint expansion and site modernization.</li>
<li>Partnership brings enhanced 5G connectivity to additional T-Mobile subscribers across the country.</li>
<li>Nokia to supply equipment from industry-leading AirScale portfolio.</li>
</ul>

Nokia Secures Multi-Year 5G RAN Deal With T-Mobile US To Expand And Modernize Nation-Leading Network

ARBE

Arbe-Powered LRR615 Imaging Radar Debuts In China Via Hirain, Offering High Sensitivity And Low False Alarm Rate

On Wednesday, following Tesla Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) <a href="https://www.benzinga.com/news/earnings/25/04/44937440/tesla-q1-misses-estimates-as-tariff-pressures-weigh-on-outlook-lower-cost-evs-still-on-track">first-quarter earnings report</a>, longtime investor and Future Fund managing partner Gary Black voiced skepticism over the company's strategy to offer lower-priced EVs.
What Happened: In a post on X, formerly Twitter, Black expressed concern that these upcoming affordable models will simply be decontented versions of the existing Model 3 and Model Y, rather than entirely new vehicles that could expand Tesla's total addressable market (TAM).
Black stated that Tesla CFO Vaibhav Taneja said during the call that these vehicles would be "within the [existing] form factor," which reinforced his view that the models may not attract new buyers but instead cannibalize sales of more expensive versions.
Black also criticized Tesla CEO Elon Musk's <a href="https://www.benzinga.com/tech/25/04/44941657/elon-musk-equates-car-ownership-in-future-to-riding-a-horse-while-using-a-flip-phone-pierre-ferragu-says-teslas-iphone-moment-hinges-on-full-autonomy">analogy comparing Tesla's EV strategy</a> to Apple Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) disruption of Nokia Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>).
See Also:&nbsp;<a href="https://benzinga.com/markets/equities/25/04/44862552/ford-recalls-nearly-150000-vehicles-over-brake-and-powertrain-issues-nhtsa" target="_blank" rel="noreferrer noopener">Ford Recalls Nearly 150,000 Vehicles Over Brake And Powertrain Issues: NHTSA</a>
He argued that without truly new vehicle types, Tesla risks repeating its 2023-2024 pattern, when price cuts led to steep earnings estimate revisions with little volume growth.
A user on X said that cheap base models don't usually sell well because buyers prefer lightly used, better-equipped versions. The user predicted that the same might happen with Tesla, too.
In response, Black said analysts are currently expecting Tesla's sales declines to ease in the second quarter and even turn positive in the fourth quarter. However, if the affordable car flops or gets delayed, then Tesla's full-year 2025 deliveries could drop even more.
&#8220;Without the new more affordable car, TSLA [deliveries] would likely be revised to -5% to -8% YoY,&#8221; he stated.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">After reviewing yesterday's <a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a> conference call transcript, we remain skeptical of TSLA's plans to introduce more affordable vehicles, which appear to be scaled down versions of existing M-Y and M-3 trims, rather than new form factors that allow <a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a> to enter new segments… <a href="https://t.co/UnAgncb6yG">pic.twitter.com/UnAgncb6yG</a>
&mdash; Gary Black (@garyblack00) <a href="https://twitter.com/garyblack00/status/1915109198129451458?ref_src=twsrc%5Etfw">April 23, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It's Important: Tesla reported first-quarter revenue of $19.34 billion, marking a 9% decline from the same period last year and falling short of Wall Street's consensus estimate of $21.35 billion.
The EV giant noted that it will revisit its 2025 guidance during the second-quarter update. Despite the revenue miss, Tesla said it maintains sufficient liquidity to support both its current product roadmap and long-term plans for capacity expansion.
Tesla also reaffirmed that its more affordable vehicle models are still on schedule to enter production in the first half of 2025. Additionally, the company announced that volume production of its autonomous Robotaxi, dubbed the Cybercab, is slated to begin in 2026.
Price Action: Tesla shares climbed 5.37% on Wednesday, ending the session at $250.74. However, the stock is still down 33.89% year-to-date, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
According to Benzinga Edge Stock Rankings, Tesla holds a growth score of 67.63%. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Click here to see how it compares with other</a> companies in the sector.
Read Next:
<ul>
<li><a href="https://benzinga.com/25/04/44855242/charlie-munger-once-highlighted-how-warren-buffetts-lifelong-learning-made-berkshire-hathaways-success-possible-and-the-crucial-lesson-you-can-take-from-it" target="_blank" rel="noreferrer noopener">Charlie Munger Once Said Warren Buffett Is A ‘Learning Machine' And That's What Lies Beneath Berkshire Hathaway's Success From One Decade To Another</a></li>
</ul>
Photo Courtesy: Trygve Finkelsen on Shutterstock.com
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

AAPL

Tesla's New Cheaper Cars Might Not Be The Game Changer Investors Hoped For, Warns Gary Black — Here's Why He Thinks They Could Hurt More Than Help

Autoliv Becomes Official Mobility Safety Partner Of Formula E To Promote Automotive And EV Safety Innovation

Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs
Performance-based and program-based payments of in total US$ 75 m to Evotec

Evotec Deepens CELMoDs Alliance With Bristol Myers Squibb As Molecular Glue Degrader Pipeline Expands

Outlook 2025
In response to macro headwinds and uncertainty around trade tariffs, the Company is optimizing its 2025 spending plan and will employ its portfolio optionality. Mitigating actions around capex, portfolio, costs and other cash initiatives are expected to offset over €2 bln of negative scenario effects.&nbsp;
<ul>
<li>FY gross capex expected to be below €8.5 bln, down from an initial guidance of around €9 bln; net capex is seen below €6 bln from an initial guidance of 6.5-7 bln.</li>
<li>At a revised scenario of 65 $/bbl for the Brent price, 40 €/MWh for the TTF gas spot price, 3.5 $/bbl for the Standard Eni Refining margin and a EUR vs USD exchange rate of 1.1, the FY Group's CFFO before working capital adjustments is expected to be at €11 bln. This reflects a better outcome than the changes to the reference scenario imply.&nbsp;</li>
<li>Oil and gas production is still expected at 1.7 mln boe/d, assuming a FY Brent price of 65 $/bbl.&nbsp;</li>
<li>FY GGP proforma adjusted EBIT is confirmed at €0.8 bln with an upside to over €1 bln in the event of positive negotiation outcomes and supportive market scenario.&nbsp;</li>
<li>Enilive and Plenitude: o FY proforma adjusted EBITDA respectively of around €1 bln and above €1.1 bln; o End of year installed renewable capacity projected at more than 5.5 GW (Plenitude @100%); biorefinery capacity at 1.65 MTPA plus 1 MTPA under construction.</li>
</ul>

Guidance

Eni Outlook 2025: Plans To Offset Over €2B In Headwinds By Cutting 2025 Capex, Streamlining Portfolio, And Tightening Costs Amid Tariff Uncertainty

FY 2025 Guidance Unchanged The Company's guidance for FY 2025 under U.S. GAAP is unchanged. Guidance assumes no material change in exchange rates for key currencies compared with FY 2024 average rates, notably USD/GBP and USD/EUR. Guidance also assumes no material change to Medicaid eligibility policy and/or other changes to Federal funding levels due to executive actions. Guidance also does not include any potential impacts from tariffs imposed by the U.S. government or any retaliatory tariffs that may be imposed by other countries. FY 2025 Net Revenue (NR) $955m to $1,025m (-17% at the mid-point vs. FY 2024) SUBLOCADE NR $725m to $765m (-1% at the mid-point vs. FY 2024) OPVEE NR $10m to $15m SUBOXONE Film Market Share Accelerated NR decline in FY 2025 reflecting increased generic competitive activity and the potential impact from a fifth buprenorphine/ naloxone sublingual film generic in the U.S. market Non-GAAP Gross Margin Low to mid-80s % range Non-GAAP SG&amp;A ($525m) to ($535m) Non-GAAP R&amp;D ($85m) to ($90m) Non-GAAP Operating Income $185m to $225m

INDV

Indivior Reaffirms 2025 Guidance: Expects Net Revenue Of $995M-$1.025B Vs. $1.046B Est.; Sees Adj. Gross Profit Of $185M-$225M

Eni (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/E#NYSE">E</a>) reported quarterly earnings of $0.76 per share. This is a 27.21 percent decrease over earnings of $1.04 per share from the same period last year. The company reported $23.74 billion in sales this quarter. This is a 4.67 percent decrease over sales of $24.91 billion the same period last year.

Eni Q1 Adj. EPADS $0.76 Down From $1.04 YoY, Sales $23.74B Down From $24.91B YoY

A new biography on Elon Musk sheds light on the billionaire entrepreneur&#8217;s Icarus moment. Hubris Maximus, by Washington Post technology reporter Faiz Siddiqui, uncovers &#8220;The Shattering of Elon Musk&#8221; across three distinct periods in recent years.
What Happened: On Wednesday, Siddiqui offered a brief glimpse of his upcoming book on Musk, discussing his opinions on CNBC&#8217;s &#8220;Squawk Box.&#8221;
Siddiqui says that his book depicts the Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO in three distinct phases, starting with the controversial <a href="https://www.benzinga.com/news/23/01/30588579/elon-musk-tweets-funding-secured-in-2018-how-much-would-1-000-in-tesla-stock-be-worth-now">&#8220;funding secured&#8221; tweet</a> in 2018, which prompted a Securities and Exchange Commission investigation, followed by the COVID-19 era, and then the acquisition of Twitter, or as it&#8217;s now called, X.
See More: <a href="https://www.benzinga.com/personal-finance/25/04/44965461/elon-musks-ex-wife-jumped-into-a-random-thread-to-answer-what-it-takes-to-be-a-billionaire-her-message-the-world-doesnt-care-what-you-want">Elon Musk&#8217;s Ex-Wife Jumped Into a Random Thread To Answer What It Takes To Be a Billionaire — Her Message: The World Doesn&#8217;t Care What You Want</a>
The book describes a pattern that Siddiqui notices with Musk, which often involves a big event, such as the acquisition of Twitter, resulting in public backlash, followed by a quiet period, and then reinvention, with Musk moving on to something else.
According to Siddiqui, his book depicts several instances of individuals who &#8220;fiercely&#8221; and &#8220;devotedly&#8221; believed in Musk&#8217;s promises, and while they still support his goals, they were &#8220;disappointed in the man.&#8221;
Unlike Icarus, the author doesn&#8217;t believe that Musk has, or is going to, crash and burn. What&#8217;s &#8220;shattered&#8221; is essentially the &#8220;veneer on Elon,&#8221; Siddiqui says. &#8220;Elon was unimpeachably our Tony Stark,&#8221; he says, but he doesn&#8217;t think that&#8217;s true anymore, thanks to the tech mogul&#8217;s &#8220;Hubris,&#8221; or exaggerated pride. 
Why It Matters: Recently, Musk&#8217;s behavior and <a href="https://benzinga.com/general/health-care/25/01/42935746/is-elon-musks-mental-health-a-cause-for-concern-biographer-thinks-so">mental health issues</a> came under scrutiny when his biographer, Seth Abramson, voiced his fears.
Musk himself has <a href="https://www.benzinga.com/general/biotech/24/03/37797951/elon-musk-on-ketamine-and-investors-value-if-there-is-something-im-taking-i-should-keep-taking-it">acknowledged and defended</a> his use of prescription Ketamine to treat occasional depressive episodes, adding that the drug has been beneficial for investors in his companies.
Back in 2017, when asked if he was bipolar by a user on Twitter, Musk replied, &#8220;Yeah,&#8221; before adding, &#8220;Maybe not medically [though].&#8221; Around the same time, he tweeted about experiencing &#8220;greater highs, terrible lows, and unrelenting stress,&#8221; hinting at bipolar disorder.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The reality is great highs, terrible lows and unrelenting stress. Don&#39;t think people want to hear about the last two.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/891710778205626368?ref_src=twsrc%5Etfw">July 30, 2017</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Despite recent turbulence, many investors and analysts continue to express confidence in Elon Musk's leadership and long-term vision. 
On Wednesday, <a href="https://www.benzinga.com/25/04/44955303/tesla-stock-is-ripping-higher-wednesday-whats-driving-the-action">Tesla shares rallied</a> after Musk announced he would scale back his involvement in the Department of Government Efficiency starting in May, a market reaction that came in spite of the company's weak first-quarter results.
Analyst Dan Ives of Wedbush Securities <a href="https://www.benzinga.com/25/04/44945402/wedbushs-dan-ives-raises-teslas-price-target-to-350-as-musk-promises-to-significantly-reduce-doge-time">raised his target</a> for Tesla to $350, a 40% upside from current levels, merely on news of Musk&#8217;s return as a full-time CEO. This comes despite a range of challenges and headwinds now facing the EV giant. This &#8220;removes the black clouds over Tesla,&#8221; Ives said, as he will be &#8220;laser-focused&#8221; on Tesla again. 
Price Action: Tesla shares rallied 5.37% on Wednesday, following the company&#8217;s much-anticipated first quarter earnings, which was released on Tuesday.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="139" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24011533/Screenshot-2025-04-23-at-1.16.03-PM-1-1024x139.png" alt="" class="wp-image-885620" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24011533/Screenshot-2025-04-23-at-1.16.03-PM-1-1024x139.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24011533/Screenshot-2025-04-23-at-1.16.03-PM-1-300x41.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24011533/Screenshot-2025-04-23-at-1.16.03-PM-1-768x104.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24011533/Screenshot-2025-04-23-at-1.16.03-PM-1-1536x208.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24011533/Screenshot-2025-04-23-at-1.16.03-PM-1.png 1592w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
According to Benzinga Edge Stock Rankings, Tesla scores well across most metrics besides value. The price trend, however, remains unfavorable in the short, medium, and long term. For more such insights, sign up for <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Benzinga Edge</a> today!
Photo Courtesy: Shutterstock.com
Read More: <a href="https://www.benzinga.com/news/global/25/04/44967548/teslas-energy-division-shines-but-etf-risks-mount-amid-broader-challenges">Tesla&#8217;s Energy Division Shines, But ETF Risks Mount Amid Broader Challenges</a>

Elon Musk Was Our Tony Stark Until He Wasn't: Tesla CEO's Icarus Moment Chronicled In New Book

Indivior (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDV#NASDAQ">INDV</a>) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.24 by 70.83 percent. This is a 10.81 percent increase over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $266.00 million which beat the analyst consensus estimate of $262.35 million by 1.39 percent. This is a 6.34 percent decrease over sales of $284.00 million the same period last year.

Indivior Q1 Adj. EPS $0.41 Beats $0.24 Estimate, Sales $266.00M Beat $262.35M Estimate

The 3iQ Solana Staking ETF (SOLQ.U) has logged impressive gains since its debut a week ago, with Cathie Wood-led Ark Invest emerging as a major buyer.
What happened: The exchange-traded fund exposes investors to the price moves of Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), the sixth-largest cryptocurrency by market capitalization, while also generating passive rewards through staking.
The investment vehicle began trading on the Toronto Stock Exchange on April 16 and has since gained around 18% in value.&nbsp;
The ETF has <a href="https://www.benzinga.com/25/04/44880757/cathie-woods-pours-another-4-95-million-into-solana-staking-etf-dumps-bitcoin-etf-again">drawn the interest of Ark</a>, the asset management firm led by experienced investor Wood.
Ark Fintech Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#BATS">ARKF</a>) holds about 482,680 shares of the ETF, amounting to a stake worth $5.43 million, according to Ark's latest reported holdings.
See Also:<a href="https://www.benzinga.com/25/04/44621245/gold-backed-cryptos-match-yellow-metals-highs-following-trumps-liberation-day-shock"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44891685/gary-black-shares-polymarket-data-says-trump-tariffs-have-pushed-odds-of-2025-recession-to-57">Gary Black Shares Polymarket Data, Says Trump Tariffs Have Pushed Odds Of 2025 Recession To 57%</a>
Notably, the underlying asset SOL has also surged, gaining 13% in the last seven days.&nbsp;The Open Interest has surged 20% over the week to $5.63 billion, <a href="https://www.coinglass.com/BitcoinOpenInterest">according</a> to Coinglass.
While U.S. regulators&nbsp;<a href="https://www.benzinga.com/25/04/44850735/solana-price-falls-but-holds-key-support-as-canadian-etf-approval-institutional-buying-offer-support" target="_blank" rel="noreferrer noopener">have yet to approve any Solana ETFs</a>, asset managers including&nbsp;VanEck,&nbsp;Bitwise, and&nbsp;Grayscale&nbsp;have filed applications.&nbsp; The odds of their approval in 2025 <a href="https://polymarket.com/event/solana-etf-approved-in-2025">stood </a>at 73% on Polymarket, a cryptocurrency-based betting platform.
Price Action: At the time of writing, SOL was exchanging hands at $148.78, down 1.52% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. Year-to-date, the cryptocurrency has fallen 21.38%. Shares of the Solana Staking ETF closed 4.17% higher at $11.73 during Wednesday&#8217;s trading session.
Meanwhile, the ARKF ETF exhibited a high momentum score as of this writing. Visit&nbsp;<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound" target="_blank" rel="noreferrer noopener">Benzinga Edge Stock Rankings</a>&nbsp;to check out how other Ark ETFs perform on this metric.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="722" height="198" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24012604/Screenshot-2025-04-24-105547.png" alt="" class="wp-image-885630" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24012604/Screenshot-2025-04-24-105547.png 722w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24012604/Screenshot-2025-04-24-105547-300x82.png 300w" sizes="(max-width: 722px) 100vw, 722px" /></figure>
Photo: Lee Wa Da/Shutterstock
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44890965/shiba-inu-team-issues-major-anti-scam-alert-heres-what-you-need-to-know">Shiba Inu Team Issues Major Anti-Scam Alert: Here&#8217;s What You Need To Know</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$SOL

ARKF

Solana Staking ETF Surges 18% In Debut Week—Here's How Much Cathie Wood's Ark Invest Has Parked In It

<ul>
<li>Investment is in addition to the ongoing partnership as shared previously, including continuing the development of BCMA targeting ANKET&#xAE; program in autoimmune indications, and more</li>
</ul>

IPHA

Innate Pharma Confirms €15M Capital Increase Backed By Sanofi To Advance ANKET® Autoimmune Pipeline

Regarding the tariff situation, there could be some short-term disruption. We will continue to utilize the flexibility of our global manufacturing network to minimize impact of the evolving tariff landscape. Based on what we see today, we currently expect a EUR 20 to 30 million impact to our comparable operating profit in the second quarter from the current tariffs. Given the lack of visibility, we have not taken an assumption related to tariffs in the second half of 2025.

Nokia Stated That Tariffs May Cut Q2 Comparable Operating Profit By €20M–€30M; No Assumptions Made For H2 2025 Due To Ongoing Uncertainty

Only 15 percent of Americans, ages 18 to 29, think the nation is headed the right way, deepening what researchers call a generational crisis of confidence.
What Happened: The <a href="https://iop.harvard.edu/youth-poll/50th-edition-spring-2025">spring</a> Harvard Youth Poll of 2,096 respondents, aged between 18 and 29 years, found 51 percent believe the country is on the wrong track and 31 percent are unsure. Just 3 percent declined to answer. Trust in Washington is equally sparse, with only 19 percent saying the federal government "does the right thing" most of the time, while fewer than one in three trust Congress, the president, or the Supreme Court.
President Joe Biden still fares better than his successor on the question of who presided over sunnier times. 41 percent say the nation was better off under Biden, compared with 25 percent for former president-turned-incumbent Donald Trump.
Trump's approval rating among young people stands at 31 percent, virtually unchanged from the same point in his first term. Trust in congressional Democrats has tumbled to 23 percent, down from 42 percent in early 2019.
See also: <a href="https://www.benzinga.com/markets/equities/25/04/44970416/scott-bessents-china-de-escalation-scoop-delivered-to-wall-street-early-at-closed-door-event-2-2-trillion-in-gains-later-questions-arise-if-retail-investors-were">Scott Bessent&#8217;s China &#8216;De-Escalation&#8217; Scoop Delivered To Wall Street Early At Closed-Door Event — $2.2 Trillion In Gains Later Questions Arise If Retail Investors Were &#8216;Cheated&#8217;</a>
Pollsters tested nine items from Trump's 2025 agenda; none topped 35 percent support. The most popular, creating a <a href="https://www.benzinga.com/startups/24/11/42069236/trump-tasked-elon-musk-to-oversee-government-efficiency-heres-how-musk-has-streamlined-costs-at-his-own-companies">Department of Government Efficiency</a>, drew barely a third of young Americans. Tariffs, abolishing the Education Department, and pardons for Jan. 6 rioters each mustered backing from two in 10 or fewer.
Why It Matters: Data from the Harvard Youth Poll coincides with the release of a new Reuters/Ipsos survey, which finds approval of Trump's handling of the economy and inflation has <a href="https://www.benzinga.com/markets/25/04/44948841/trump-economic-approval-rating-drops-to-37-as-market-selloff-erodes-public-support-poll">slid to 37 percent</a>, down from 42 percent recorded just after his Jan. 20 inauguration. Together, the polls paint a picture of mounting public unease as Trump nears his 100-day mark.
Other gauges echo the turbulence. <a href="https://www.benzinga.com/news/25/04/44890428/trumps-gallup-approval-stands-at-45-topping-same-point-in-first-presidency-but-hes-down-16-in-economist-survey">Gallup</a> put Trump's overall approval at 45 percent in April — up from 41 percent at the same point in his first term — while an Economist/YouGov survey reported a 16-point plunge since January. An <a href="https://www.benzinga.com/news/global/25/03/44183107/trumps-approval-rating-48-voters-disapprove-of-handling-of-russia-ukraine-war-55-think-world-war-to-happen">Emerson College poll</a> in March showed a steadier 49 percent rating, even as opinions split over his handling of the Russia-Ukraine war. However, the latest Reuters/Ipsos figures suggest a sustained downward trend tied to economic anxieties and jittery financial markets.
Photo Courtesy: Joshua Sukoff on Shutterstock.com
Read next: <a href="https://www.benzinga.com/markets/equities/25/04/44970516/boeing-adjusts-strategy-amid-trump-tariff-fallout-ceo-kelly-ortberg-says-wont-build-aircraft-for-customers-who-will-not-take-them-as-china-halts-deliveries">Boeing Adjusts Strategy Amid Trump Tariff Fallout, CEO Kelly Ortberg Says Won&#8217;t &#8216;Build Aircraft For Customers Who Will Not Take Them&#8217; As China Halts Deliveries</a>

Government

Politics

Events

Trump Fails To Impress America's Young, Shows Poll As They Still Favor Biden — Only 15% Think US On Right Track

Guidance confirmed&nbsp;
<ul>
<li>In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER5 . Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER (before share buyback)6&nbsp;</li>
<li>Sanofi intends to complete a share buyback program in 2025 of €5 billion of which 72% was already repurchased</li>
</ul>

Sanofi Reaffirms 2025 Guidance: Sales To Grow Mid-To-High Single Digits (CER), Business EPS To Rise Low Double Digits (CER)

Press Releases

Relmada Therapeutics to Present at Jefferies London Healthcare Conference

Legal

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Health Care

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Relmada Therapeutics To Present NDV-01 Data at AUA2025

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Athira Pharma

Aytu BioPharma

Biofrontera

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

Cocrystal Pharma

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Durect

Hoth Therapeutics

Impact BioMedical

IGC Pharma

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lipocine

Lyra Therapeutics

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

ProPhase Labs

Pulmatrix

Scilex Holding

Talphera

Traws Pharma

TherapeuticsMD

Mizuho

Leerink Partners

Jefferies

Goldman Sachs

RELMADA THERAPEUTICS by Relmada Therapeutics, Inc.

편집자 주: 오늘은 &#8220;언더 더 레이더(Under The Radar)&#8221;의 미리보기를 제공합니다. &#8220;언더 더 레이더&#8221;는 아무도 이야기하지 않는 수익 기회를 매주 소개하는 이메일로, Benzinga Edge 회원 전용입니다. 매주 화요일 &#8220;언더 더 레이더&#8221;를 받아보시고, 다양한 트레이드 아이디어, 분석 및 투자 도구를 원하신다면, <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9spmirebz65&amp;utm_source=RD-1010">여기서 Benzinga Edge에 가입하세요.</a>.
매일 많은 이야기와 논의가 내부자 매수에 대해 인터넷에 올라온다. 대부분은 기업 내부자들의 매수 및 매도 활동에 대한 연구가 책 표지의 소개글을 읽는 데 그치는 사람들에 의해 작성된 것처럼 보인다.
일부 내부자 매수는 중요하다. 반면, 일부는 도움이 거의 안된다.
어떤 내부자가 현재 시장의 인기 주식을 매도하고 있다는 이유로 주식 시장의 종말이 올 것이라고 과장된 이야기를 들을 수 있지만, 실제로 그러한 매도는 거의 항상 의미가 없다.
대규모 기관이 소규모 회사 주식을 추가로 매입하는 경우, 이는 큰 내부자 매수로 나타날 수 있다. 하지만 이러한 정보는 미래 수익의 지표로서 무의미하다.
대부분의 옵션 행사 및 주식 지급은 예측 가치 측면에서 무가치하다.
어떤 내부자 매수가 가치 있는 정보를 포함하는지 아는 것은, 내부자 활동을 투자 또는 거래 활동의 기준으로 사용할 경우 중요하다.
보세요, 내부자 중에서는 회사의 주식을 공개 시장에서 매입할 때마다 꾸준히 성공하는 그룹이 있다.
그들은 C-레벨 임원들이다. 이들은 회사에 대한 큰 결정을 내리고 일상적인 운영 및 결과를 보고 싶어하는 사람들이다.
그들은 공중뿐만 아니라 다른 임원 및 이사회 구성원보다도 상당한 정보 우위를 가지고 있다.
이 먹이 사슬에서 위로 올라갈수록 내부 거래에서 큰 돈을 벌 확률이 높아진다. CEO와 CFO가 가장 높은 성공 확률을 가지고 있다.
이들 두 사람 중 CEO가 우위를 갖고 있지 않다. CEO는 회사에 대한 모든 일이 계획대로 진행되고 있음을 본다. CFO는 모든 날마다 숫자와 현금 흐름을 살펴보며, 모든 결정이 회사의 수익과 재무 상태에 어떤 영향을 미칠지를 이해한다.
역사적으로, 이러한 우위는 CFO가 회사 주식을 공개 시장에서 매입할 때 매우 높은 수익을 올릴 수 있게 해주었다.
여기 &#8220;언더 더 레이더(Under the Radar)&#8221;에서는 내부자 활동과 관련된 연구 결과를 읽고 데이터를 분석하는 데 상당한 시간을 투자했다. 가장 큰 교훈 중 하나는, 똑똑한 투자자들이 CFO가 수표를 꺼낼 때 주목한다는 것이다.
올해 주식 시장은 매우 강세를 보였기 때문에 내부자 매도가 매수 활동보다 훨씬 더 많았다.
내부자들은 대개 바겐 헌터이며, 최근에는 바겐을 찾기가 어려웠다.
최근, 주목할 만한 CFO 매수가 두 건 있었다.
1. 엡실론 에너지(EPSN)의 CFO인 앤드류 윌리엄스(Andrew Williams)는 최근 회사 주식을 공개 시장에서 6자리 수로 매입하고 있다.
그가 주식을 현재 시장 가격보다 약간 낮은 가격에 매입했지만, 3분기 동안 낮은 수준의 석유와 가스는 회사의 3분기 실적 발표 시 실적 실망으로 이어질 가능성이 높다.
엡실론은 향후 몇 년 동안 천연가스 수요 증가로 인해 막대한 장기 수익 증가를 경험할 수 있는 위치에 있다.
최근 CFO는 재무 모델링을 수행했으며, 우리와 마찬가지로 상승하는 천연가스 가격이 엡실론의 수익에 미치는 영향이 회사 주가를 극적으로 상승시킬 것임을 이해하고 있다.
엡실론 주식의 진정한 기회는 향후 몇 년 동안 구매 가격의 몇 배에 이를 잠재력이며, 회사가 관대한 배당금을 지급한다는 점도 나쁘지 않다.
현재 가격에서 엡실론 주식은 4% 이상의 배당 수익률을 제공한다.
저는 생명공학이나 제약 개발에 대해 아는 바가 없으며, 대부분의 인터넷 전문가들이 약물 승인 프로세스와 어떤 약물이 성공할 것인지에 대해 잘 알지 못한다고 의심한다.
그러나 C-레벨 임원들은 모든 것이 어떻게 진행되는지, 또는 승인을 받거나 더 큰 회사와 거래를 성사시킬 경우 주식의 잠재력이 어떤지를 잘 알고 있다.
그 누구보다도 CFO는 이러한 긍정적인 발전이 회사 수익에 어떤 영향을 미칠지를 정확히 알고 있다.
최고재무책임자(CFO)가 자신이 감독하는 회사의 주식에 6자리 수로 투자할 가치가 있다고 판단할 때, 그것은 주목할 만한 일이다.
2. 렐마다 테라퓨틱스(RLMD)는 중추신경계 질환 치료를 위한 신약을 개발하고 있다. 이 회사는 저용량 실로시빈을 대사 질환 치료제로 사용하는 방법도 연구하고 있으며, 다른 약물 시험도 진행 중이다.
저는 실로시빈(psilocybin)이 어떤 치료제로 쓰인다는 것에 대해 1970년대 록 밴드 그레이트풀 데드(Grateful Dead) 공연 몇 번을 제외하고는 아는 바가 없다.
CFO인 마지드 셰누다(Maged Shenouda)는 회사가 개발하고 있는 약물과 그것이 수익 및 주가에 미칠 영향에 대해 저보다 훨씬 더 많이 알고 있다.
그는 올해 정기적으로 주식을 공개 시장에서 매입하고 있으며, 최근 몇 주 전에도 6자리 수의 공개 시장 매입을 하였다.
그는 혼자가 아니다. CEO도 주식을 지속적으로 대량으로 매입하고 있다.
여기서 흥미로운 점이 있다.
제프리스(Jefferies)라는 증권 및 연구 회사가 최근 별다른 홍보 없이 주식을 매수로 상향 조정하였고, 현재 3상 시험 중인 약물이 회사에 큰 성공이 될 가능성이 있다고 언급했다. 애널리스트 앤드류 차이(Andrew Tsai0는 목표 주가를 14달러로 상향 조정했다.
두 주식 모두 주요 언론과 대부분의 월스트리트의 주목을 받지 못하고 있다.
CFO들이 맞다면, 두 주식은 현재 주가의 몇 배에 달하는 수익을 올릴 가능성이 있다.
주가 움직임: 엡실론의 주식은 목요일 1.66% 상승한 6.14달러에 마감되었다. 이 주식은 올해 들어 19.69% 상승했다. 반면 렐마다의 주식은 2.06% 하락한 3.33달러에 마쳤다. 이 주식은 올해 들어 23.80% 하락했다.
매주 화요일, Benzinga Edge 회원들은 이렇게 &#8220;Under The Radar&#8221; 이야기를 받아볼 수 있으며, 다른 트레이드 아이디어, 투자 분석 등도 주중 내내 받을 수 있습니다. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9spmirebz65&amp;utm_source=RD-1010">Benzinga Edge에 가입하세요.</a>
이미지 생성은 Midjourney를 사용했습니다.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Relmada Therapeutics

뉴스

에 대한 최신 뉴스 Relmada Therapeutics (NASDAQ:RLMD) 주식

금요일, 10월 11, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌